Enable Injections, a leading innovator in wearable drug delivery technology, has announced the expansion of its partnership with Roche. This collaboration will utilize Enable's enFuse® platform, a state-of-the-art wearable device that facilitates the subcutaneous delivery of large volumes of medication. This technology allows patients to bypass traditional intravenous (IV) administration, providing a simpler and potentially more comfortable treatment experience.
As part of the agreement, Roche has secured worldwide exclusive rights to combine specific drugs from their portfolio with the enFuse technology. This strategic alliance aims to revolutionize the way medications are administered, particularly benefiting patients requiring frequent and long-term treatments. Enable Injections will be responsible for the clinical and commercial manufacturing and supply of the enFuse systems under the partnership.
Mike Hooven, Chairman and CEO of Enable Injections, emphasized the advantages of enFuse over traditional IV infusions, which are often inconvenient and time-consuming for both patients and healthcare providers. He highlighted that the enFuse technology is designed to address these challenges by offering a fast, simple, and convenient delivery method. This innovation not only enhances patient autonomy by enabling at-home self-administration but also brings efficiency and value to the healthcare system as a whole.
Click here to read the original news story.